Integrated assessment of potential value of erbB-2 amplification or expression status as novel therapy target in Chinese children and adolescents with osteosarcoma / 中华医学杂志(英文版)
Chinese Medical Journal
; (24): 1521-1524, 2009.
Article
in En
| WPRIM
| ID: wpr-292678
Responsible library:
WPRO
ABSTRACT
<p><b>BACKGROUND</b>Targeted tumor therapies have been making rapid progress in recent years, and the erbB-2 oncogene is a suitable target. There was much discussion about the level of erbB-2 in osteosarcoma. The aim of this study was to investigate the erbB-2 amplification or expression status in osteosarcoma.</p><p><b>METHODS</b>Fluorescence in situ hybridization (FISH) and DNA probes for erbB-2 and centromere 17 were used to examine the erbB-2 gene amplification status in 32 osteosarcoma samples, and expression of erbB-2 was analyzed by immunohistochemistry (IHC) and reverse transcription-polymerase chain reaction (RT-PCR).</p><p><b>RESULTS</b>None of the 32 osteosarcomas was observed by FISH to have the erbB-2 gene amplified, and no distinguishable membrane staining was seen in any case yet, nevertheless, erbB-2 overexpression was present in 6 tumor samples by RT-PCR.</p><p><b>CONCLUSIONS</b>The status of erbB-2 gene amplification and membrane overexpression is rare in osteosarcomas, and might suggest that the erbB-2 target agent should not be applied to osteosarcomas as single treatment.</p>
Full text:
1
Index:
WPRIM
Main subject:
Therapeutics
/
Bone Neoplasms
/
Osteosarcoma
/
Gene Amplification
/
In Situ Hybridization, Fluorescence
/
Receptor, ErbB-2
/
Genes, erbB-2
/
Dimerization
/
Reverse Transcriptase Polymerase Chain Reaction
/
Genetics
Limits:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Language:
En
Journal:
Chinese Medical Journal
Year:
2009
Type:
Article